NIM811, a cyclophilin inhibitor without immunosuppressive activity, is beneficial in collagen VI congenital muscular dystrophy models

作者：Zulian Alessandra; Rizzo Erika; Schiavone Marco; Palma Elena; Tagliavini Francesca; Blaauw Bert; Merlini Luciano; Maraldi Nadir Mario; Sabatelli Patrizia; Braghetta Paola; Bonaldo Paolo; Argenton Francesco; Bernardi Paolo^*

来源：Human Molecular Genetics, 2014, 23(20): 5353-5363.

DOI：10.1093/hmg/ddu254

Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) are inherited muscle diseases due to mutations in the genes encoding the extracellular matrix protein collagen (Col) VI. Opening of the cyclosporin A-sensitive mitochondrial permeability transition pore (PTP) is a causative event in disease pathogenesis, and a potential target for therapy. Here, we have tested the effect of N-methyl-4-isoleucine-cyclosporin (NIM811), a non-immunosuppressive cyclophiiin inhibitor, in a zebrafish model of CoIVI myopathy obtained by deletion of the N-terminal region of the CoIVI alpha 1 triple helical domain, a common mutation of UCMD. Treatment with antisense morpholino sequences targeting coI6a1 exon 9 at the 1-4 cell stage (within 1 h post fertilization, hpf) caused severe ultrastructural and motor abnormalities as assessed by electron and fluorescence microscopy, birefringence, spontaneous coiling events and touch-evoked responses measured at 24-48 hpf. Structural and functional abnormalities were largely prevented when NIM811 which proved significantly more effective than cyclosporin A was administered at 21 hpf, while FK506 was ineffective. Beneficial effects of NIM811 were also detected (i) in primary muscle-derived cell cultures from UCMD and BM patients, where the typical mitochondrial alterations and depolarizing response to rotenone and oligomycin were significantly reduced; and (ii) in the CoI6a1(-/-) myopathic mouse model, where apoptosis was prevented and muscle strength was increased. Since the PTP of zebrafish shares its key regulatory features with the mammalian pore, our results suggest that early treatment with NIM811 should be tested as a potential therapy for UCMD and BM.

• 出版日期2014-10-15